Cell Therapy
9
5
5
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
11.1%
1 terminated out of 9 trials
50.0%
-36.6% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (9)
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
Safety and Efficacy of FAP iCDC in Ischemic Cardiomyopathy
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence
Cell Therapy With Cellistem-OA for Symptomatic Knee Osteoarthritis